Campbell's Co. says sales rise as more Americans cook meals at home
The Campbell's Co. said Monday it saw stronger sales of broth and condensed soup in its latest quarter as more Americans cooked their meals at home.
'Consumers continue to cook at home and focus their spending on products that help them stretch their food budgets, and they're increasingly intentional about their discretionary snack purchases,' Campbell's President and CEO Mick Beekhuizen said during a conference call with investors.
Beekhuizen said Campbell's saw the highest level of meals cooked at home since early 2020 in its fiscal third quarter, which ended April 27. Campbell's noted sales of its broths rose 15% during the quarter while sales of its Rao's pasta sauces were up 2%.
But Campbell's said sales of its snacks, including Goldfish crackers and Cape Cod potato chips, fell 4% during the quarter.
Other big companies, including McDonald's, have also noted that Americans are increasingly eating at home as uncertainty over the economy grows. Grocery prices have also moderated. In 2024, prices for food eaten at home rose 1.2%, while prices for food away from home rose 4.1%, according to the U.S. Department of Agriculture.
Snack makers like PepsiCo, which makes Frito Lay chips, and General Mills, which makes Bugles chips and Golden Grahams, have also noted lower demand for snacks in recent quarters.
Campbell's net sales rose 4% to $2.5 billion for the fiscal third quarter, which was in line with Wall Street's expectations, according to analysts polled by FactSet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
19 minutes ago
- Epoch Times
FTC Warns of Rising Student Loan Scams, Says Fraudsters Took Millions From Borrowers
The Federal Trade Commission (FTC) is The warning, issued June 6, comes as part of a broader push by the FTC to raise awareness about deceptive debt-relief schemes targeting Americans with student loans.
Yahoo
27 minutes ago
- Yahoo
Trump Vows To ‘Rapidly Defeat Inflation' To Help ‘Millions and Millions' of Americans Achieve Their ‘Dream of Homeownership'
President Donald Trump has boldly promised to 'rapidly bring down inflation' to make homeownership more accessible to millions of Americans while addressing the National Association of Realtors® Legislative Meetings 2025 in a pre-recorded speech. Speaking to industry leaders, the pre-recorded video aired at the Washington, DC, event, the president said he believes that reducing inflation will in turn help to bring down interest rates, a move that will put homeownership 'within the reach of millions and millions for the first time in years.' 'I love people that are in the real estate business,' Trump began. 'I have a little bit of a proclivity for it. You play a vital role in helping Americans achieve the dream of homeownership, and together, we will make the American dream more attainable than ever before. 'We are working to rapidly defeat inflation, which will bring down interest rates and put homeownership within the reach of millions of millions for the first time in years.' April's inflation rate—2.3%—is 'much lower than expected,' Trump noted. 'Likewise, income soared by 0.8% in one month, almost triple expectations and close to record territory. Mortgage rates are down, we're slashing unnecessary regulations, and we are working to pass the largest tax cuts and reforms in American history.' April's inflation rate is the lowest since February 2021, but it's not expected to motivate the Federal Reserve to lower interest rates. The Fed will be meeting mid-June and will announce any decision on rates when it wraps up its two days of meetings. Meanwhile, Trump has repeatedly slammed Jerome Powell for not taking further action—despite the Fed chair claiming that longer-term rates will likely remain higher because of the risk of 'volatile' inflation. Homebuying help is at hand Affordability has been a major challenge for potential buyers despite home listing inventory seeing gains in regions like the West (+40.7% year over year) and the South (+32.9% YoY), according to the May 2025 Monthly Housing Report. Mortgage rates continue to hover near the 7% mark—which is leading potential buyers to take their time committing to a home. New listings also inched up last week—up 4.2% compared with the same time last year. Homeowners looking to build a new home are also faced with challenges, as Trump's 50% tariffs on steel and aluminum took effect on June 5. 'Higher tariffs on steel and aluminum are likely to raise the cost of key construction materials, and these added costs could be passed through to homebuyers through higher home prices,' says Hannah Jones, senior economic research analyst at Following this latest tariff hike by Trump last week, the National Association of Home Builders continued to express concern over the toll the increased costs will have on homebuilders—and the wider housing market. 'President Trump's move to double steel and aluminum tariffs will have a negative impact on housing affordability by further disrupting building material supply chains and fueling business uncertainty,' NAHB Chairman Buddy Hughes told But Trump, in his pre-recorded speech to the NAR, thanked industry leaders for their support of the 'big, beautiful bill,' which is currently sitting with the Senate for review. 'I want to thank the Realtors® for your support of the one big, beautiful bill, the most important piece of legislation in many years,' said Trump. 'This landmark legislation, in fact, will preserve the small-business tax deductions and so many want and need, [that] so many real estate agents are just demanding. 'It will stop trillions of dollars in tax hikes on American families and put more money in the pockets of homebuyers by raising take-home pay for the typical family by an estimated $13,000. Think of that, $13,000 with your help, a record number of Americans will achieve financial independence and find a home that really fits their dreams and aspirations, something very, very beautiful.' The tax and spending package is expected to cut trillions from the budget, but the Congressional Budget Office said it's going to add trillions to the national debt. The president is pushing the Senate to approve the bill and get it to his desk to sign by July 4. Ties with leaders at every level A president's remarks at the NAR meetings has been a tradition since 1921. For example, NAR has invited every sitting president to its yearly conference. The first time Trump was in office, he delivered a live speech to attendees in 2019. Herbert Hoover, Ronald Reagan, Bill Clinton, and George W. Bush are among the past presidents to speak at the conference. NAR said it does not pay a fee for a president to speak.
Politico
33 minutes ago
- Politico
How much money will the FDA get next year?
Presented by Driving The Day FDA APPROPS INCHES FORWARD — House appropriators advanced a bill to fund the FDA for fiscal 2026 on a party-line vote out of a subcommittee Thursday — but the bill has a long path ahead before it potentially becomes law. The topline number from the House bill aligns with President Donald Trump's budget proposal, which sought $6.8 billion for the FDA. That includes $3.2 billion in direct appropriations, with the remainder coming from user fee revenue. But that represents roughly a $300 million cut in taxpayer funding compared to what the House Appropriations subcommittee sought last year for fiscal 2025 — a fact Democrats seized on during the hearing. 'We need to embrace transparency, and the FDA should be able to effectively and quickly share information,' said Rep. Sanford Bishop (D-Ga.), ranking member of the subcommittee, which is in charge of approving funds for the FDA. 'It needs the resources to do this.' But Rep. Andy Harris(R-Md.), subcommittee chair, said the figure represents 'modest constraint' that will still allow Americans access to a safe food and drug supply. But the Senate is likely to fund the agency at a higher level than the House. The Republican senator in charge of FDA appropriations, Sen. John Hoeven (R-N.D.), told Prescription Pulse on Wednesday that Trump's proposal is a starting point. 'We now have the president's budget proposal,' Hoeven said. 'But we're going through our process now, and it will be different. … I think that you'll see when we bring it out that we adequately fund FDA.' IT'S FRIDAY. WELCOME BACK TO PRESCRIPTION PULSE. We can't help but notice the FDA's advice for the 'fellas' cautioning about over-the-counter sexual enhancement supplements. Send your tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). POLITICO PRO SPACE — Need an insider's guide to the politics behind the new space race? From battles over sending astronauts to Mars to the ways space companies are vying to influence regulators, this weekly newsletter decodes the personalities, policy and power shaping the final frontier. Find out more. Eye on the FDA CELLS IN THE SPOTLIGHT — The FDA's top biologics regulator said Thursday he's willing to consider surrogate endpoints — markers believed to correlate with clinical benefit in a drug — as part of the agency's approach to approving rare-disease therapies by using 'gold-standard science and common sense.' 'We will rapidly make available therapies at the first sign or promise of biomedical success or action, but we're also going to follow up overall survival and quality of life on the back end,' Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, said during an agency roundtable on cell and gene therapies. Prasad added he's often asked whether he's 'solely' interested in randomized controlled trials and said he's open to a variety of methodologies demonstrating a drug's benefit. Background: His remarks come weeks after he and Commissioner Marty Makary unveiled a new Covid-19 vaccine framework that limits approvals of future formulation changes to people 65 and older and younger individuals with an underlying condition — and requiring new RCTs to prove the shots are safe and effective for young, healthy people. Cell and gene therapies are often discussed in the context of rare diseases, as the technologies can address root causes instead of solely managing symptoms. But a condition's rarity hinders a company's ability to conduct a large-scale trial for a drug candidate, an issue with which regulators and industry have long struggled. The FDA launched a rare-disease 'hub' last year to better align its drug and biologics regulators in their approach to considering those therapies for the market. In Congress O'NEILL CONFIRMED — The Senate voted to confirm Jim O'Neill to be HHS deputy secretary by a 52-43 vote Thursday — elevating an ally of early Trump backer and tech billionaire Peter Thiel, who previously worked as HHS principal associate deputy secretary during the George W. Bush administration. O'Neill advocated in 2014 for the FDA to approve drugs once they're verified as safe, instead of also requiring effectiveness data — and was considered as an FDA commissioner candidate during President Donald Trump's first term. REPUBLICANS PLAN SUPPLY-CHAIN HEARING — Top Republican health lawmakers on the House Energy and Commerce Committee want to reduce America's reliance on other countries for medicines and other health care products — and plan to hold a hearing Wednesday on how to incentivize a stronger supply chain. 'We have long been champions of policies that support efforts to onshore U.S.-based manufacturing and bolster our domestic supply chain, while, at the same time, strengthening our national security interests and economic goals,' E&C Chair Brett Guthrie (R-Ky.) and Health Subcommittee Chair Buddy Carter (R-Ga.) said in a news release. Over in the Judiciary Committee, lawmakers are scheduled to examine the 'privacy and national security implications' of the 23andMe bankruptcy Wednesday at 10:15 a.m. A BIPARTISAN PUSH? Lawmakers on both sides of the aisle indicated Wednesday that reauthorizing the FDA's over-the-counter user fee program could be a bipartisan effort — and the agency's over-the-counter sunscreen regulation has yielded bipartisan frustration. Sen. Bill Cassidy (R-La.), chair of the Senate Health, Education, Labor and Pensions Committee, and other lawmakers questioned the FDA's top drug regulator why more drugs are not being moved to OTC status more rapidly — and Democrats questioned if job cuts at the FDA could impact new approvals. Document Drawer The FDA granted Florida a second extension for its drug importation program, extending the state's authorization to Nov. 6. But before drug imports can start, importers must file a pre-import request, which the FDA must grant, making it unclear whether the program will be used. The top FDA medical device regulator, Dr. Michelle Tarver, met with Johnson and Johnson last week to discuss 'general medical device updates,' according to a public calendar disclosure. Also last week, the FDA deputy commissioner for strategic initiatives, Lowell Zeta, met with Eli Lilly to discuss 'pharmaceutical updates.' The Government Accountability Office convened a roundtable of 19 experts to discuss how HHS can improve testing efforts during a public health emergency and released a report containing their nearly 100 recommendations. WHAT WE'RE READING STAT's Elaine Chen explores how Novo Nordisk's recent challenges competing with Eli Lilly relate to a cautious culture at the Danish drugmaker.
